Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL
Official Title: Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial
Brief Summary: This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with excess blasts.
Blasts are immature blood cells.
Decitabine is in a class of medications called hypomethylation agents.
It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.
Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF.
It is in a class of medications called kinase inhibitors.
It works by blocking the action of an abnormal protein that signals cancer cells to multiply.
This helps slow or stop the spread of cancer cells.
Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors.
It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
The combination of ASTX727 and venetoclax may be more effective in reducing the cancer signs and symptoms in patients with CMML, or MDS/MPN with excess blasts.